Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
Fulgent Genetics announced that its abstract regarding FID-007 was selected for a Rapid Oral presentation at the 2026 ASCO Annual Meeting. The Phase 2 study evaluates FID-007 in combination with cetuximab for patients with recurrent or metastatic head and neck squamous cell carcinoma.
Key figures
- Drug Name
- FID-007
- Phase Of Trial
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.